NCT06536465

The Clostridioides Difficile Trial of REC-3964

A Phase 2 Clinical Study of REC-3964 in Adults for the Reduction of Recurrent Clostridioides Difficile Infection (CDI)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Recursion Pharmaceuticals Inc. · Industry
• Sex: All
• Age: 18 Years – 115 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC-3964 (doses of either 250 mg or 500 mg PO every 12 hours) for the reduction of Clostridioides difficile infection (CDI).

Detailed description

Study was terminated due to sponsor decision. This decision was not related to safety concerns.

Conditions

• Recurrent Clostridioides Difficile Infection

Interventions

Type	Name	Description
DRUG	REC-3964	REC-3964 given at a dose of either 500 mg q12h or 250 mg q12h

Timeline

• Start date: 2024-10-14
• Primary completion: 2025-05-06
• Completion: 2025-05-06
• First posted: 2024-08-05
• Last updated: 2025-11-17
• Results posted: 2025-11-17

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study